MMF, the ester prodrug of the immunosuppressant mycophenolic acid (MPA), acts at a late stage of lymphocyte proliferation, beyond the steps where either corticosteroids of CsA have inhibitory activity. It noncompetitively and reversibly inhibits inosine monophosphate dehydrogenase, the key enzyme in the pathway of de novo purine synthesis. In contrast to other cells, T and B lymphocytes rely on this pathway to synthesise guanosine nucleotides which are required for DNA and RNA synthesis. Thus, MMF hampers the proliferation of lymphocytes and the production of antibodies. 1 In patients undergoing renal and heart transplantation, it has been successfully used to prevent graft rejection. 2, 3 The bioavailability of orally administered MMF is 94% in healthy individuals. After absorption, MMF is rapidly hydrolysed to the active compound MPA. 4 MPA undergoes enterohepatic circulation. However, plasma levels of MPA in allogeneic blood stem cell transplantation were much lower than expected, eventually due to intestinal toxicity after high-dose conditioning. 5 Thus, an intravenous (i.v.) application of MMF may be advantageous.
Since GvHD significantly contributes to morbidity and mortality after matched unrelated donor (MUD) transplantation, more effective prophylaxis therapy is needed. MMF has been shown to be of potential value in the allogeneic stem cell transplantation. 6, 7 In this open single-centre phase II study, we evaluated the efficacy of MMF in the prophylaxis of GvHD, by adding MMF to standard GvHD prophylaxis with a short-course MTX and CsA. 8 
Materials and methods

Patients
Between April 1999 and September 2002, 30 patients with advanced haematological malignancies were enrolled in this study at the transplant unit of the Department for Internal Medicine II (Oncology and Haematology), University Hospital Jena, Germany. Patient characteristics are summarised in Table 1 . The study was approved by the local Ethical Review Board, and each patient provided written, informed consent.
Conditioning regimen
The standard transplant-preparative regimen consisting of 12 Gray (Gy) fractionated total body irradiation (TBI) (lung shielding to 8.6 Gy) in combination with 120 mg/kg bodyweight of cyclophosphamide (CY) i.v. was used in 13 patients (43.3%). One patient additionally received 60 mg/ kg bodyweight etoposide (VP16). For reasons such as prior treatment toxicities or comorbidity including infection and age, reduced conditioning regimen consisting of fludarabine (6 Â 30 mg/m 2 ) busulfan (8 mg/kg per bodyweight) and antithymocyte globulin (ATG) (Fresenius s ) in a dose of 4 Â 10 mg/kg per bodyweight was used in 16 patients (53.3%). 9 
HLA typing
HLA A and B antigens were typed by serologic methods and HLA DRB1 alleles with sequence-specific oligonucleotide probes, respectively. Donors were required to match the recipients for the serological defined HLA A and B antigens as well as HLA DRB1 alleles. In all, 26 patients were transplanted with a matched unrelated donor, while four patients received a transplant from an unrelated donor with a single antigen mismatch.
Grafts
All grafts were peripheral blood stem cells mobilised by granulocyte colony-stimulating factor (G-CSF) (Filgastrim 
Supportive care and GvHD prophylaxis
All patients were nursed under a strict hygienic regimen in HEPAR s air-filtered rooms established at our unit for high-risk allogeneic transplantation. This includes total gut decontamination with broad-spectrum antibiotics and antifungal medication to prevent severe GvHD 10 and standard prophylaxis against Pneumocystis carinii infection. All patients received G-CSF (5 mg/kg) subcutaneously beginning on day 1 after transplantation, and continued until the absolute white blood cell count was 41.0 Â 10 9 /l for 3 consecutive days.
All blood products were irradiated with 30 Gy and patients with negative cytomegalovirus (CMV) serology received CMV-negative blood products only. Standard GvHD prophylaxis consisted of cyclosporine (CSA) 3 mg/ kg bodyweight as continuous infusion from day À1 until day þ 30 in combination with methotrexate (MTX) 15 mg/ m 2 at day þ 1, and 10 mg/m 2 on days þ 3, þ 6, respectively, until day þ 11. In case of the reduced condition regimen, MTX was omitted. Starting on day þ 10 until day þ 40 after transplantation, patients received additionally 1 g MMF (Cellcept R , Hofmann La Roche, Germany) i.v. every 12 h. At the time of discharge, all medications were switched to oral application.
Chimerism studies
After transplantation, donor chimerism was monitored in sex-mismatched transplantation by FISH analysis or by variable numbers of tandem repeat (VNTR) polymerase chain reaction (PCR).
Statistical analysis
The incidence of acute GvHD was calculated according to the method of Kaplan and Meier.
Results
Engraftment
All patients showed a leucocyte engraftment on median day þ 12 (range 9-22) and platelet engraftment 420 000 Â 10 9 / l on median day þ 14.5 (range 10-61). There was no graft failure. On a median of day þ 36 (range 15-72), patients were discharged from the hospital. They received a medium number of 12 packed red blood cell transfusions (range 6-28) and 14 platelet transfusions from single-donor apheresis (range 5-49).
Acute and chronic GvHD
Acute and chronic GvHD were graded according to common clinical criteria. 11, 12 Acute GvHDXII was observed in 19 patients (63%). Two patients (6.6%) had grade III and three patients (10%) grade IV GvHD (Figure 1 ). In all, 23 patients survived until day 100, and were evaluable for chronic GvHD (Table 2) . Limited chronic GvHD occurred in nine (39.1%) patients and extensive chronic GvHD developed in two (8.7%) patients. A total of 26.3% of patients with acute GvHDXII developed secondary limited chronic GvHD, and 10.5% extensive chronic GvHD, respectively. Three patients developed de novo limited and none extensive chronic GvHD, requiring additional immunosuppression with prednisolone (2 mg/kg bodyweight). Interestingly, there was a trend towards a higher incidence of acute GvHDXII in patients receiving myeloablative (71.4%) compared with reduced conditioning regimen (56.3%).
Survival and treatment-related mortality
With a median follow-up of 28 months (range 9-46), 16 (53.3%) patients are alive with a disease-free survival of 50%. Seven patients relapsed, one of whom received a second matched unrelated transplant. A total of 14 (46.6%) patients died due to relapse (n ¼ 6, at 3, 5, 7, 15, 17, and 19 months), thrombotic-thrombolytic microangiopathy (TMA) (n ¼ 2, at 3 and 6 months), acute GvHD grade IV (n ¼ 2, at 1 and 3 months), infection (n ¼ 2, at 1 and 3 months), toxicity (n ¼ 1, at 1 month), and subdural bleeding (n ¼ 1, at 3 months), respectively (Table 4 ).
Cytomegalovirus infections
Of 13 patients, 10 were CMV IgG positive and became positive for pp65, indicating reactivation of CMV. Only one patient who was CMV IgG negative and received a CMV IgG-negative transplant showed a CMV antigenaemia (Table 3) . Patients received pre-emptive treatment with gancyclovir, and there was no death related to a CMV infection.
Toxicity MMF-related side effects were moderate. Most patients reported nausea and vomiting, and in three patients (10%) the drug has to be terminated early on a median of day þ 17 (range þ 16 to þ 17), one of whom developed GvHD III. However, drug-associated toxicity could not exactly be distinguished from other reasons in this phase 2 trial. 
Discussion
The outcome of allogeneic stem cell transplantation for patients with haematological disorders is negatively influenced by significant acute and chronic GvHD. In related donor HLA-matched allografts, acute GvHD develops in approximately 30-60% of recipients. However, using MUD or HLA-mismatched donors, the prevalence may become 90%, 14, 15 including an expected GvHD grade III and IV of 35-47%. 16 Acute GvHD is associated with high morbidity and mortality, and chronic GvHD develops in 35-50% of surviving patients.
Effective immunosuppressive regiments are required to prevent GvHD. The common agents are CsA, MTX, prednisolon or combinations thereof. However, such treatment itself may be associated with significant toxicities: nephrotoxicity with CsA or tarcolimus, hyperglycaemia, infections, avascular necrosis and osteoporosis with glucocorticoids, and mucositis and hyperbilirubinaemia with MTX. Therefore, new immunosuppressive strategies are warranted. In contrast to the calcineurin inhibitors CsA and tacrolimus, MMF has no negative effect on chimerism or tolerance development. 17 Since MMF acts at a late stage of T-and B-lymphocyte proliferation, it is an interesting drug in combination with standard immunosuppression.
So far, few studies have demonstrated the efficacy of MMF in the prevention and treatment of GvHD following allogeneic stem cell transplantation. [18] [19] [20] [21] In this trial, we used a different schedule in a high-risk patient population, starting with MMF on day þ 10 in combination with CsA for reduced conditioning regimens, or CsA and MTX for myeloablative treatment. No graft failure was seen. The observed incidence of 63% acute GvHDXII and of 48% chronic GvHD were below the expected rate. In particular, the incidences of severe acute (10%) or extensive chronic GvHD (8.7%) were low in this high-risk patient population (Figure 1 ). There was even a trend towards a reduced incidence in patients receiving a reduced conditioning. However, this may be due to the use of ATG in the reduced conditioning schedule. Since ATG has a long half-life, it may have been an effective immunosuppressive regiment in the first month after transplantation.
Recently, the combination of tacrolimus and MTX after unrelated donor transplantation has been shown to significantly reduce the risk of acute GvHD than the combination of cyclosporine and MTX. 22 The probabilities of grade II-IV GvHD in this study were 56 and 74%, respectively. Additionally, the GvHD prophylaxis with tacrolimus and MTX was associated with a reduced risk of chronic GvHD. 23 Thus, a randomised trial comparing this combination in addition to MMF would be of interest.
In all, 78% of the patients being seropositive for CMV developed a CMV antigenaemia, and had to be treated with gancyclovir. CMV disease and mortality in the recipients of allogeneic haematopoietic stem cell transplants corresponds to viral load and T-cell immunity. 24 In patients receiving nonmyeloablative allogeneic stem cell transplantation, CMV disease is significantly delayed, but the overall 1-year incidence is similar to myeloablative conditioning. 25 Previously, MMF treatment has been identified as a significant risk factor for both overall and complicated CMV infections. 26 However, in our patient population, no patient with CMV antigenaemia developed a CMV infection due to strict pre-emptive treatment.
In conclusion, MMF seems to be safe and feasible in the prophylaxis of severe acute GvHD for high-risk patients. However, there appears to be an increased risk for reactivating CMV in seropositive patients.
